Back to Trades
Total Value
$0
Filing Date
Nov 20, 2026
1 transactions
Trade Summary
On Nov 18, 2026, PharmaCyte Biotech, Inc., 10% Owner, reported $0 of Q/C TECHNOLOGIES, INC. (QCLS) across 1 transactions. The filing covers Common stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Q/C TECHNOLOGIES, INC.
- Ticker Symbol
- QCLS
- CIK
- 0001321834
Insider Information
- Role
- 10% Owner
- Location
- LAS VEGAS, NV
Filing Details
- Filing Date
- Nov 20, 2026
- Transaction Date
- Nov 18, 2026
- Accession Number
- 0001683168-26-009018
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Nov 18, 2026 | Common stock | 4,982,272 | ā | Exercise | ā |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Nov 18, 2026 | Series G Long-Term Warrants | 851,304 | ā | Exercise | ā |
| Nov 18, 2026 | Series H Convertible Preferred Stock | 3,000 | ā | Other | ā |
Want live alerts when PharmaCyte Biotech, Inc. trades again?
Download Insider Trades to track QCLS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement.
- (F2)Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder.
- (F3)Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment.
- (F4)Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment.
- (F5)On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d)